Furthermore, stratification of survival data of patients with pancreatic cancer based on SAT1 expression showed a significantly lower overall survival in patients with high SAT1 expression (median survival, 498 days) as compared to patients with low SAT1 expression (median survival, 1,332 days) (Fig. 7h). Here, SAT1 is linked to pancreatic neoplasm.